This vaccine was evaluated in patients in the United Kingdom and in Hong Kong, China with NPC and induced specific CD4+ and CD8+ T cell responses to EBNA1 and LMP2, respectively.45 This evidence concerns the gene CD8A and nasopharyngeal carcinoma.